Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibrx Biosciences

14.43
-0.3600-2.43%
Post-market: 14.430.00000.00%18:08 EDT
Volume:393.15K
Turnover:5.68M
Market Cap:208.89M
PE:0.13
High:14.75
Open:14.66
Low:14.26
Close:14.79
Loading ...

Inhibrx Biosciences Inc. Conducted Annual Shareholder Meeting Virtually

Reuters
·
29 May

Inhibrx Q1 EPS $(2.80) Beats $(2.84) Estimate

Benzinga
·
15 May

Inhibrx Biosciences Reports Q1 2025 Results: Net Loss Narrows to $43.3M, EPS Improves to $2.80

Reuters
·
15 May

Inhibrx Q1 Operating Expenses USD 42.901 Million

THOMSON REUTERS
·
15 May

Inhibrx Biosciences Signs Deal With Outgoing CSO Brendan Eckelman's New Venture

MT Newswires Live
·
02 Apr

Inhibrx Biosciences Appoints New President Amid Leadership Changes

TIPRANKS
·
02 Apr

BRIEF-Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President

Reuters
·
02 Apr

Inhibrx Biosciences Announces Departure of Cso and Appointments of New Cso and President

THOMSON REUTERS
·
02 Apr

Inhibrx Biosciences Inc - Enters Exclusive License Agreement With New Company

THOMSON REUTERS
·
02 Apr

Inhibrx Biosciences Inc - Appoints Carlos Bais as Cso and David Matly as President

THOMSON REUTERS
·
02 Apr

Press Release: Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Dow Jones
·
02 Apr

Inhibrx Biosciences Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
19 Mar

Inhibrx Q4 Net Income $(47.9)M Or $(3.09) Per Share

Benzinga
·
18 Mar

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

PR Newswire
·
18 Mar

Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities

TIPRANKS
·
22 Jan

Inhibrx Prospective Colorectal Cancer Treatment Shows Encouraging Results, Trial Expansion Planned

MT Newswires Live
·
22 Jan

Inhibrx Biosciences Reports Promising Trial Results for INBRX-109

TIPRANKS
·
22 Jan

Inhibrx announces preliminary ozekibart data, initiates new expansion cohort

TIPRANKS
·
22 Jan

Inhibrx Biosciences Inc - Phase 1 Trial Shows 1 Complete Response, 3 Partial Responses, 6 Stable Disease Cases

THOMSON REUTERS
·
22 Jan

Inhibrx Biosciences Announces Preliminary Data From the Phase 1 Trial of Ozekibart (Inbrx-109) for the Treatment of Colorectal Cancer

THOMSON REUTERS
·
22 Jan